文献库搜索 | GeneLibs

Xu(JJ),Ni(CX),Xu(JJ) World J Gastroenterol 2026-02-14

...BRAF, implying a potential synergistic interaction between impaired DNA repair mechanisms and activation of oncogenic pa...

Almahari(SA),Al-Ani(M),Zaitoun(AM),Gordon(... Front Oncol None

...BRAF fusion alongside oncogenic variants: TERT c.-124C>T (VAF 0.60) and TP53 c.811G>A p. (Glu271Lys) (VAF 0.90). Targete...

Zhao(Q),Zhao(K),Song(J),Zhao(W) BMC Cancer 2026-02-16

...BRAF could obtain PFS benefit from third-line ICI over non-ICI treatment. Thirty-six (38.7%) patients developed at least...

Shintani(T),Hamada(A),Yamasaki(S),Jono(Y),... In Vitro Cell Dev Biol Anim 2026-05-00

...BRAF and NRAS mutations; however, a GNAS mutation was identified. The OS-MM cell line should contribute to advances in p...

De Mattia(M),Boutros(A),Delucchi(V),Blonde... BMC Cancer 2026-02-21

...BRAF-mutant melanoma, 33 (72%) received BRAF/MEK inhibitors. At three months before death, 80 (86%) patients remained on...

Sako(A),Hirokawa(M),Matsuse(M),Higuchi(M),... J Pathol Transl Med 2026-03-00

...BRAFV600E mutation, particularly for NS3 tumors. We performed genetic analysis on 92 archival thyroid tumor samples, inc...

Yokoyama(Y),Nishio(N),Sugiura(M),Suzuki(K)... JCEM Case Rep 2026-02-00

...BRAF V600E pathogenic variant, leading to treatment with encorafenib and binimetinib, initiated on postoperative day 24....

Yang(L),He(Y),Peng(Y),Sun(M),Tang(Z),Du(L)... Front Oncol None

...BRAF-V600E mutations emerge as a resistance mechanism to EGFR tyrosine kinase inhibitors. While the combination of BRAF/...

Yamin(T),Cohen(O),Robenshtok(E),Izkhakov(E... Front Endocrinol (Lausanne) None

...BRAF and MEK inhibitors. All patients had confirmed BRAF V600E mutation. Among three patients treated with BRAF/MEK inhi...

Ruan(Y),Chen(L),Xia(S),Lu(Q),Wang(J),Zhu(F... Front Pediatr None

...BRAF variants were detected in the diseased brain tissue, with mosaic levels of 20.2% and 13.5%, respectively. Matched t...